iSpecimen (ISPC) Stock Price, News & Analysis

Company Overview

iSpecimen, Inc. (NASDAQ:ISPC) operates an online life sciences marketplace designed to connect researchers with human biological specimens and associated clinical data. The company’s platform streamlines the sourcing of biospecimens—such as plasma, serum, fresh and frozen tissue, saliva, urine and peripheral blood mononuclear cells (PBMCs)—by matching demand from pharmaceutical, biotechnology, diagnostic and academic organizations with supply from a wide network of clinical sites and biobanks.

Through its on-demand procurement model, iSpecimen provides customized specimen collection and fulfillment services that help accelerate research timelines and improve data quality. Clients can specify criteria such as disease state, treatment history, demographics and sample processing requirements, while the company manages regulatory compliance, informed consent documentation and quality assurances in accordance with HIPAA, FDA and international guidelines.

Founded in 2015 and headquartered in Boston, Massachusetts, iSpecimen has gradually expanded its footprint to include partnerships with specimen providers across North America and select global markets. The company leverages its proprietary technology and centralized logistics to reduce lead times and deliver specimens and data under controlled chain-of-custody conditions. Over time, iSpecimen has supported thousands of research studies spanning oncology, neurology, immunology, cardiovascular disease and infectious disease.

Under the leadership of founder and CEO Eddie Clarke, iSpecimen continues to evolve its platform by adding new specimen types, enhancing data annotation tools and forging collaborations with contract research organizations and diagnostic developers. The company’s marketplace model aims to address critical bottlenecks in translational and clinical research by making high-quality human biospecimens more accessible to investigators worldwide.

Key Stats

• Today's Range: $5.30 to $6.24
• 50-Day Range: $4.27 to $11.38
• 52-Week Range: $4.00 to $127.20
• Volume: 588,804 shs
• Average Volume: 679,999 shs
• Market Capitalization: $4.39 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

iSpecimen Stock Analysis - MarketRank™

iSpecimen scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

iSpecimen has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

iSpecimen has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of iSpecimen is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of iSpecimen is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

iSpecimen has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

21.23% of the float of iSpecimen has been sold short.

Short Interest Ratio / Days to Cover

iSpecimen has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in iSpecimen has recently increased by 852.04%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

iSpecimen does not currently pay a dividend.

Dividend Growth

iSpecimen does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 4 news articles for iSpecimen this week, compared to 2 articles on an average week.

Search Interest

13 people have searched for ISPC on MarketBeat in the last 30 days. This is an increase of 63% compared to the previous 30 days.

MarketBeat Follows

3 people have added iSpecimen to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, iSpecimen insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.20% of the stock of iSpecimen is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

13.62% of the stock of iSpecimen is held by institutions.

ISPC Stock Analysis - Frequently Asked Questions

How have ISPC shares performed this year?

iSpecimen's stock was trading at $10.4040 at the start of the year. Since then, ISPC shares have decreased by 40.5% and is now trading at $6.19.

How were iSpecimen's earnings last quarter?

iSpecimen Inc. (NASDAQ:ISPC) released its quarterly earnings results on Monday, November, 17th. The company reported ($19.20) EPS for the quarter, beating the consensus estimate of ($152.00) by $132.80. The company had revenue of $0.11 million for the quarter, compared to the consensus estimate of $3.33 million. iSpecimen had a negative net margin of 543.37% and a negative trailing twelve-month return on equity of 496.31%.

When did iSpecimen's stock split?

iSpecimen shares reverse split on the morning of Tuesday, April 28th 2026.A 1-40 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 27th 2026. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

When did iSpecimen IPO?

iSpecimen (ISPC) raised $20 million in an initial public offering on Tuesday, June 15th 2021. The company issued 2,250,000 shares at a price of $8.00-$10.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO.

How do I buy shares of iSpecimen?

Shares of ISPC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of iSpecimen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that iSpecimen investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD), Arista Networks (ANET) and Braze (BRZE).

Company Calendar

• Last Earnings: 11/17/2025
• Today: 5/05/2026
• AGM 2026: 5/08/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:ISPC
• CIK: 1558569
• Web: ispecimen.com
• Phone: 781-301-6700
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($94.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$10.49 million
• Net Margins: -543.37%
• Pretax Margin: -543.70%
• Return on Equity: -496.31%
• Return on Assets: -133.56%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.12
• Quick Ratio: 1.12

Sales & Book Value

• Annual Sales: $1.93 million
• Price / Sales: 2.35
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $14.57 per share
• Price / Book: 0.42

Miscellaneous

• Outstanding Shares: 740,000
• Free Float: 651,000
• Market Cap: $4.53 million
• Optionable: Not Optionable
• Beta: 1.75